TY - JOUR
T1 - COVID-19–related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders
T2 - A cross-sectional survey
AU - Mikocka-Walus, Antonina
AU - Skvarc, David
AU - van Tilburg, Miranda A.L.
AU - Barreiro-de Acosta, Manuel
AU - Bennebroek Evertsz, Floor
AU - Bernstein, Charles N.
AU - Burisch, Johan
AU - Ferreira, Nuno
AU - Gearry, Richard B.
AU - Graff, Lesley A.
AU - Jedel, Sharon
AU - Mokrowiecka, Anna
AU - Stengel, Andreas
AU - Knowles, Simon
N1 - Funding Information:
Outside the present work, A. Mikocka‐Walus served as an invited speaker at IBD‐related conferences co‐organized by Crohn's & Colitis Australia (a charity), Janssen and Ferring, and received a speaker's fee. M. Barreiro‐de Acosta has served as a speaker, consultant, and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gilead, Pfizer, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte, and Vifor Pharma. Ch. Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Janssen Canada, Roche Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; consultant for Mylan Pharmaceuticals and Takeda; educational grants from AbbVie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada; speaker’s panel for AbbVie Canada, Janssen Canada, Takeda Canada, and Medtronic Canada; and received research funding from AbbVie Canada. L. Graff has served as a consultant for Roche Canada. R. Gearry has served on advisory boards for AbbVie New Zealand and Australia, Janssen New Zealand; speaker’s panel for AbbVie New Zealand and Australia, Janssen New Zealand, Takeda Australia; and educational grants from AbbVie, New Zealand. A. Stengel has worked as consultant for a + r Berlin, Boehringer Ingelheim, Dr. Wilmar Schwabe, Microbiotica, and Takeda. I. Trindade has received consultancy fees from Pfizer Inc. M van Tilburg has served as a consultant for Mahana Therapeutics, Inc. Outside the present work, S.R Knowles served as an invited speaker at IBD‐related conferences co‐organized by Crohn's & Colitis Australia (a charity) and Coeliac Australia (a charity), is a member of the Medical Advisory Committee for Glutagen Pty Ltd, and has received consultancy fees from AbbVie Pty Ltd and Janssen‐Cilag Pty Ltd.
Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021
Y1 - 2021
N2 - Background: The mental health response to the coronavirus (COVID-19) pandemic–related product shortages in those living with chronic gastrointestinal (GI) disorders has received little attention. We aimed to explore the association between the pandemic-related product shortages and psychological distress in people with GI disorders. Methods: This online cross-sectional survey was nested within an ongoing, international, prospective study of well-being in people with GI disorders. The study was advertised in multiple countries in May-September 2020 via patient organizations and social media. The primary outcome measure was distress, evaluated by the Depression Anxiety Stress Scale. We utilized linear regressions, adjusting for covariates and testing individual moderation effects. Key Results: Overall, 831 people completed the survey from 27 countries, of whom 82% were female (mean age = 49 years). The most common disorders included inflammatory bowel disease (n = 322), celiac disease (n = 273), and irritable bowel syndrome (n = 260). Significant problems accessing food were reported by 19.8%, non-medical therapies by 16%, toilet paper by 10.8%, and essential medication by 8.9% of the sample (>5% pain medication). There was a positive association between toilet paper and pain medication shortages and distress, and a negative association between food shortages and distress. Significant moderation effects were identified for COVID-19 prevalence and toilet paper and food shortages, and between COVID-19 fear and pain medication shortages. Conclusions and Inferences: The study documented a significant relationship between product shortages and psychological distress, which were associated with COVID-19 prevalence and fear. Strategies addressing COVID-19 fear could potentially modify the relationship between shortages and distress.
AB - Background: The mental health response to the coronavirus (COVID-19) pandemic–related product shortages in those living with chronic gastrointestinal (GI) disorders has received little attention. We aimed to explore the association between the pandemic-related product shortages and psychological distress in people with GI disorders. Methods: This online cross-sectional survey was nested within an ongoing, international, prospective study of well-being in people with GI disorders. The study was advertised in multiple countries in May-September 2020 via patient organizations and social media. The primary outcome measure was distress, evaluated by the Depression Anxiety Stress Scale. We utilized linear regressions, adjusting for covariates and testing individual moderation effects. Key Results: Overall, 831 people completed the survey from 27 countries, of whom 82% were female (mean age = 49 years). The most common disorders included inflammatory bowel disease (n = 322), celiac disease (n = 273), and irritable bowel syndrome (n = 260). Significant problems accessing food were reported by 19.8%, non-medical therapies by 16%, toilet paper by 10.8%, and essential medication by 8.9% of the sample (>5% pain medication). There was a positive association between toilet paper and pain medication shortages and distress, and a negative association between food shortages and distress. Significant moderation effects were identified for COVID-19 prevalence and toilet paper and food shortages, and between COVID-19 fear and pain medication shortages. Conclusions and Inferences: The study documented a significant relationship between product shortages and psychological distress, which were associated with COVID-19 prevalence and fear. Strategies addressing COVID-19 fear could potentially modify the relationship between shortages and distress.
KW - COVID-19
KW - distress
KW - gastrointestinal disorders
KW - product shortages
KW - psychological distress
UR - http://www.scopus.com/inward/record.url?scp=85108220659&partnerID=8YFLogxK
U2 - 10.1111/nmo.14198
DO - 10.1111/nmo.14198
M3 - Article
AN - SCOPUS:85108220659
SN - 1350-1925
JO - Neurogastroenterology and Motility
JF - Neurogastroenterology and Motility
ER -